Vaxcyte (PCVX) Stock Price & Analysis

PCVX$63.37-1.32 -2.04%
BiotechnologyLarge CapGrowth Stock
Compare
Market cap$10.03BEnterprise value$8.29BRevenue (TTM)$0Market positionTop 25%

Score

66
Bullish
Value
57
Quality
40
Growth
100

AI Analysis

Snapshot

Vaxcyte is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 66/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~93% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

40
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Vaxcyte, Inc. (PCVX) last printed $63.37. Equity value is $10.03B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Vaxcyte (PCVX) Stock Price & Analysis

PCVX price $63.37 -1.32 -2.04%

Ticker
PCVX
Price
$63.37
Change
-1.32 -2.04%
Market cap
$10.03B
Forward P/E
28.94
Dividend yield
0.00%
Beta
1.29
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
66
Value
57
Quality
40
Growth
100

Stocklytics score rationale: value 57, quality 40, growth 100.

AI Score 30. Vaxcyte, Inc. has a market cap of $10.34 billion but is in the clinical development stage with no revenue reported, leading to a negative net income margin of 0%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener